



Arbutus Presents HBV Data at Upcoming Scientific Conferences

September 22, 2017

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of HBV data at the following scientific conferences.

Discovery on Target: Targeting HBV, Sept 25, 2017, Boston, MA

Presentations Include:

- RNA Interference: A New Tool in the Toolbox for Treatment of HBV *by Amy Lee, Senior Director, Research*
- HBV Capsid Assembly Inhibitors *by Rene Rijnbrand, Vice President, Head of Biology*

Discovery on Target: Emerging Oligonucleotide Therapeutics, Sept 27-28, 2017, Boston, MA

Presentation Includes:

- RNAi Based Human Therapy for Chronic Hepatitis B Infection *by Amy Lee, Senior Director, Research*

These presentations will be available by visiting the Investor section of www.arbutusbio.com and selecting Events and Presentations.

About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: acutler@arbutusbio.com

Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: ttolmie@arbutusbio.com

Media

David Schull
Russo Partners
Phone: 858-717-2310
Email: david.schull@russopartnersllc.com

[Primary Logo](#)

Source: Arbutus Biopharma Corporation